Janis Silins of the Association of Biopharmaceutical Drug Manufacturers in Latvia discusses the organization’s purpose, collaboration efforts, and role in shaping policy reform.
Could you please start by introducing the Association of Biopharmaceutical Drug Manufacturers in Latvia (Biofarmaceitisko Ražotāju Asociācijas Latvijā (BRAL)) and your role within the association?
"We strive to play a proactive role in fostering the emergence of a financially sustainable and high-performance healthcare system in which patients gain ready access to first class, effective therapies"
